Before leaving her role as US generics COO, Christine Baeder discussed paying for quality, generic confidence, redundancy and predicting shortages in a Pink Sheet interview.
Paying for quality has become a popular catch phrase and solution to the drug shortage problem, but Christine Baeder, the recently departed chief operating officer for US generics and biosimilar at Teva Pharmaceutical Industries Ltd., worries the current proposals won’t actually live up to the hype and could harm more than help the generic industry.
Baeder spoke to Pink Sheet on the sidelines of the Milken Institute Future of Health Summit in November, just weeks...
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
